Loading stock data…
DMRA
$25.36-0.30 (-1.17%)
Market ClosedLast close May 1
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Damora Therapeutics, Inc. in the Healthcare sector is trading at $25.36. The stock is currently 34% below its 52-week high of $38.33, remaining 48.1% above its 200-day moving average. Technical signals show neutral RSI of 43 and bearish MACD signal, explaining why DMRA maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 43) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$25.36
Potential Upside
5%
Whystock Fair Value$26.63
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that target...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.54B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.60
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-87.29%
Volume
Today's trading volume
228,109
Recent News
Damora Faces Upside As Fast-Follower CALR 'Should Make Bigger Splash,' RBC Says
Damora Therapeutics (DMRA) is capitalizing on growing validation of using mutant calreticulin target
What Makes Galecto, Inc. (DMRA) a Strong Momentum Stock: Buy Now?
Does Galecto, Inc. (DMRA) have what it takes to be a top stock pick for momentum investors? Let's find out.
How Much Upside is Left in DAMORA THERAPEU (DMRA)? Wall Street Analysts Think 73.1%
The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in DAMORA THERAPEU (DMRA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Damora Therapeutics (DMRA) Overhauls Leadership: Is Its Capital Strategy About To Quietly Shift?
Damora Therapeutics recently appointed Jennifer Jarrett as its new Chief Executive Officer and President, overhauled several Board seats, and issued sizeable equity awards tied to these leadership changes. The combination of Jarrett’s deep biopharma and capital markets background with new directors from Blueprint Medicines and Spyre Therapeutics points to a potentially different approach to funding and portfolio execution. Next, we’ll examine how installing Jennifer Jarrett as CEO and...